Protective role of natural IgM-producing B1a cells in atherosclerosis

Research output: Contribution to journalArticleResearchpeer-review

37 Citations (Scopus)

Abstract

Atherosclerosis initiated by hyperlipidemia is modulated by immune cells in its development, progression, and rupture that results in thrombotic arterial occlusion leading to strokes and myocardial infarction. B cells initially thought to be atheroprotective provide opposing roles by their different subsets. Unlike B2 cells that are atherogenic, serosal B1a cells are atheroprotective by producing natural IgM antibodies that clear modified low-density lipoprotein and apoptotic and necrotic debris. In addition to natural IgM antibodies, B1a cells may act as regulatory B cells by producing the anti-inflammatory cytokine interleukin-10, which inhibits proinflammatory cytokines secreted by activated macrophages and T cells in atherosclerotic lesions. These findings suggest in vivo expansion of atheroprotective B1a cells as a potential therapeutic strategy to augment the benefits of lipid-lowering statin therapy.
Original languageEnglish
Pages (from-to)48 - 53
Number of pages6
JournalTrends in Cardiovascular Medicine
Volume22
Issue number2
DOIs
Publication statusPublished - 2012

Cite this

@article{53038dec4a3a486ca4fb8fde371f0f94,
title = "Protective role of natural IgM-producing B1a cells in atherosclerosis",
abstract = "Atherosclerosis initiated by hyperlipidemia is modulated by immune cells in its development, progression, and rupture that results in thrombotic arterial occlusion leading to strokes and myocardial infarction. B cells initially thought to be atheroprotective provide opposing roles by their different subsets. Unlike B2 cells that are atherogenic, serosal B1a cells are atheroprotective by producing natural IgM antibodies that clear modified low-density lipoprotein and apoptotic and necrotic debris. In addition to natural IgM antibodies, B1a cells may act as regulatory B cells by producing the anti-inflammatory cytokine interleukin-10, which inhibits proinflammatory cytokines secreted by activated macrophages and T cells in atherosclerotic lesions. These findings suggest in vivo expansion of atheroprotective B1a cells as a potential therapeutic strategy to augment the benefits of lipid-lowering statin therapy.",
author = "Kyaw, {Tin Soe} and Tipping, {Peter George} and Alexander Bobik and Ban-Hock Toh",
year = "2012",
doi = "10.1016/j.tcm.2012.06.011",
language = "English",
volume = "22",
pages = "48 -- 53",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier",
number = "2",

}

Protective role of natural IgM-producing B1a cells in atherosclerosis. / Kyaw, Tin Soe; Tipping, Peter George; Bobik, Alexander; Toh, Ban-Hock.

In: Trends in Cardiovascular Medicine, Vol. 22, No. 2, 2012, p. 48 - 53.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Protective role of natural IgM-producing B1a cells in atherosclerosis

AU - Kyaw, Tin Soe

AU - Tipping, Peter George

AU - Bobik, Alexander

AU - Toh, Ban-Hock

PY - 2012

Y1 - 2012

N2 - Atherosclerosis initiated by hyperlipidemia is modulated by immune cells in its development, progression, and rupture that results in thrombotic arterial occlusion leading to strokes and myocardial infarction. B cells initially thought to be atheroprotective provide opposing roles by their different subsets. Unlike B2 cells that are atherogenic, serosal B1a cells are atheroprotective by producing natural IgM antibodies that clear modified low-density lipoprotein and apoptotic and necrotic debris. In addition to natural IgM antibodies, B1a cells may act as regulatory B cells by producing the anti-inflammatory cytokine interleukin-10, which inhibits proinflammatory cytokines secreted by activated macrophages and T cells in atherosclerotic lesions. These findings suggest in vivo expansion of atheroprotective B1a cells as a potential therapeutic strategy to augment the benefits of lipid-lowering statin therapy.

AB - Atherosclerosis initiated by hyperlipidemia is modulated by immune cells in its development, progression, and rupture that results in thrombotic arterial occlusion leading to strokes and myocardial infarction. B cells initially thought to be atheroprotective provide opposing roles by their different subsets. Unlike B2 cells that are atherogenic, serosal B1a cells are atheroprotective by producing natural IgM antibodies that clear modified low-density lipoprotein and apoptotic and necrotic debris. In addition to natural IgM antibodies, B1a cells may act as regulatory B cells by producing the anti-inflammatory cytokine interleukin-10, which inhibits proinflammatory cytokines secreted by activated macrophages and T cells in atherosclerotic lesions. These findings suggest in vivo expansion of atheroprotective B1a cells as a potential therapeutic strategy to augment the benefits of lipid-lowering statin therapy.

UR - http://www.ncbi.nlm.nih.gov/pubmed/22841841

U2 - 10.1016/j.tcm.2012.06.011

DO - 10.1016/j.tcm.2012.06.011

M3 - Article

VL - 22

SP - 48

EP - 53

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

IS - 2

ER -